Setbacks For China Pharma As Firms Hit With Antitrust Fine, Clinical Setback
One of China's largest domestic pharma conglomerates has been fined more than $100m for price-fixing and other monopoly acts, while another firm has seen a major Phase III setback for its global launch hope.
You may also be interested in...
US-based, China-focused CANbridge moves into cholestatic liver disease and enzyme replacement therapy via two deals. Plus deals involving LegoChem, TransThera, Morepen, Daiichi Sankyo, Geneseeq, Innocare, Biosplice, Sirnaomics and Walvax.
As the US responds to calls to waive intellectual property rights related to COVID-19 vaccines, China is already moving ahead with some of its own mRNA candidates.
Amid controversy over vaccines protection efficacy, China overhauls its disease control system with a brand-new agency to oversee disease control and prevention measures.